Healthcare provider profile · identity verified

Maria T Muriente, MD

General Practice · DAVENPORT, FL · NPI 1861658478

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	641	245
Levothyroxine Sodium	Levothyroxine Sodium	332	109
Losartan Potassium	Losartan Potassium	301	108
Metformin Hcl	Metformin Hcl	293	107
Amlodipine Besylate	Amlodipine Besylate	284	108
Lisinopril	Lisinopril	246	95
Gabapentin	Gabapentin	237	97
Hydrochlorothiazide	Hydrochlorothiazide	214	87
Albuterol Sulfate Hfa	Albuterol Sulfate	146	58
Pantoprazole Sodium	Pantoprazole Sodium	144	64
Omeprazole	Omeprazole	129	62
Famotidine	Famotidine	118	42
Montelukast Sodium	Montelukast Sodium	117	44
Alendronate Sodium	Alendronate Sodium	116	51
Rosuvastatin Calcium	Rosuvastatin Calcium	94	38
Vitamin D2	Ergocalciferol (Vitamin D2)	94	45
Furosemide	Furosemide	83	29
Metoprolol Tartrate	Metoprolol Tartrate	83	35
Trazodone Hcl	Trazodone Hcl	76	23
Fluticasone Propionate	Fluticasone Propionate	74	35
Meloxicam	Meloxicam	73	28
Metoprolol Succinate	Metoprolol Succinate	73	36
Glipizide	Glipizide	72	31
Ciprofloxacin Hcl	Ciprofloxacin Hcl	71	56
Simvastatin	Simvastatin	70	32
Ibuprofen	Ibuprofen	68	42
Buspirone Hcl	Buspirone Hcl	60	26
Azithromycin	Azithromycin	58	51
Alprazolam	Alprazolam	56	15
Ozempic	Semaglutide	55	19
Sertraline Hcl	Sertraline Hcl	54	24
Glimepiride	Glimepiride	53	17
Pravastatin Sodium	Pravastatin Sodium	52	13
Clopidogrel	Clopidogrel Bisulfate	51	21
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	50	39
Eliquis	Apixaban	50	14
Fenofibrate	Fenofibrate Nanocrystallized	47	23
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	45	27
Folic Acid	Folic Acid	45	19
Tramadol Hcl	Tramadol Hcl	42	18
Zolpidem Tartrate	Zolpidem Tartrate	42	12
Memantine Hcl	Memantine Hcl	40	18
Tamsulosin Hcl	Tamsulosin Hcl	40	17
Carvedilol	Carvedilol	39	16
Baclofen	Baclofen	38	16
Meclizine Hcl	Meclizine Hcl	38	21
Atenolol	Atenolol	35	13
Clonidine Hcl	Clonidine Hcl	34	15
Ezetimibe	Ezetimibe	34	suppressed
Nabumetone	Nabumetone	33	27
Clonazepam	Clonazepam	30	12
Tizanidine Hcl	Tizanidine Hcl	30	suppressed
Donepezil Hcl	Donepezil Hcl	29	11
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	29	11
Mounjaro	Tirzepatide	29	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	28	26
Januvia	Sitagliptin Phosphate	28	suppressed
Enalapril Maleate	Enalapril Maleate	27	11
Naproxen	Naproxen	27	17
Synthroid	Levothyroxine Sodium	27	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	25	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	25	suppressed
Metformin Hcl Er	Metformin Hcl	25	11
Acyclovir	Acyclovir	23	suppressed
Diclofenac Sodium	Diclofenac Sodium	23	suppressed
Irbesartan	Irbesartan	22	suppressed
Nitrofurantoin	Nitrofurantoin Macrocrystal	22	19
Cephalexin	Cephalexin	21	20
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	21	suppressed
Methylprednisolone	Methylprednisolone	21	16
Neomycin-Polymyxin-Hydrocort	Neomycin/Polymyxin B/Hydrocort	21	19
Nifedipine Er	Nifedipine	21	suppressed
Prednisone	Prednisone	21	14
Allopurinol	Allopurinol	20	suppressed
Duloxetine Hcl	Duloxetine Hcl	20	suppressed
Glipizide Er	Glipizide	20	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	20	suppressed
Clobetasol Propionate	Clobetasol Propionate	19	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	19	suppressed
Xarelto	Rivaroxaban	19	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	18	suppressed
Lovastatin	Lovastatin	18	suppressed
Methotrexate	Methotrexate Sodium	18	suppressed
Topiramate	Topiramate	18	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	18	12
Trulicity	Dulaglutide	18	suppressed
Spironolactone	Spironolactone	17	suppressed
Citalopram Hbr	Citalopram Hydrobromide	16	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	16	suppressed
Fluconazole	Fluconazole	16	11
Jardiance	Empagliflozin	16	suppressed
Ondansetron Hcl	Ondansetron Hcl	16	11
Fenofibrate	Fenofibrate	15	suppressed
Hydralazine Hcl	Hydralazine Hcl	15	suppressed
Metronidazole	Metronidazole	15	suppressed
Potassium Chloride	Potassium Chloride	15	suppressed
Sildenafil Citrate	Sildenafil Citrate	15	suppressed
Dexamethasone	Dexamethasone	14	13
Lantus	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Paroxetine Hcl	Paroxetine Hcl	14	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	14	suppressed
Valsartan	Valsartan	14	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	14	suppressed
Bumetanide	Bumetanide	13	suppressed
Finasteride	Finasteride	13	suppressed
Nitroglycerin	Nitroglycerin	13	suppressed
Sucralfate	Sucralfate	13	suppressed
Symbicort	Budesonide/Formoterol Fumarate	13	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	13	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	13	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	12	suppressed
Digoxin	Digoxin	12	suppressed
Divalproex Sodium	Divalproex Sodium	12	suppressed
Halobetasol Propionate	Halobetasol Propionate	12	suppressed
Lorazepam	Lorazepam	12	suppressed
Naproxen Sodium	Naproxen Sodium	12	11
Benzonatate	Benzonatate	11	suppressed
Chlorthalidone	Chlorthalidone	11	suppressed
Diclofenac Potassium	Diclofenac Potassium	11	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	11	suppressed
Tadalafil	Tadalafil	11	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error